Cargando…

Comparative Effectiveness of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors and Human Glucagon-Like Peptide-1 (GLP-1) Analogue as Add-On Therapies to Sulphonylurea among Diabetes Patients in the Asia-Pacific Region: A Systematic Review

The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers. Whereas some of the established oral hypoglycaemic drug classes li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Martin C. S., Wang, Harry H. X., Kwan, Mandy W. M., Zhang, Daisy D. X., Liu, Kirin Q. L., Chan, Sky W. M., Fan, Carmen K. M., Fong, Brian C. Y., Li, Shannon T. S., Griffiths, Sian M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948731/ https://www.ncbi.nlm.nih.gov/pubmed/24614606 http://dx.doi.org/10.1371/journal.pone.0090963

Ejemplares similares

Dipeptidyl peptidase-4 (DPP-4; CD26)
Publicado: (2013)

In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy
por: Araújo, F., et al.
Publicado: (2016)

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19
por: Solerte, Sebastiano Bruno, et al.
Publicado: (2020)

Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
por: Sebastián-Martín, Alba, et al.
Publicado: (2022)

Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis
por: Salvo, Francesco, et al.
Publicado: (2016)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
por: Zhang, Tianli, et al.
Publicado: (2021)

Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis
por: Schulz, Kirsten, et al.
Publicado: (2015)

Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes
por: Zilleßen, Pia, et al.
Publicado: (2016)

Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis
por: Lee, Jung Min, et al.
Publicado: (2019)

Dipeptidyl Peptidase 4 (DPP4) as A Novel Adipokine: Role in Metabolism and Fat Homeostasis
por: Barchetta, Ilaria, et al.
Publicado: (2022)

Cardiovascular outcomes of type 2 diabetic patients treated with DPP‑4 inhibitors versus sulphonylureas as add-on to metformin in clinical practice
por: Bazo-Alvarez, Juan Carlos, et al.
Publicado: (2021)

A theoretical investigation on the geometries of glucagon-like peptide-1 and its interactions with dipeptidyl peptidase DPP-IV
por: Brickmann, Jürgen, et al.
Publicado: (2008)

Drosophila as a Rapid Screening Model to Evaluate the Hypoglycemic Effects of Dipeptidyl Peptidase 4 (DPP4) Inhibitors: High Evolutionary Conservation of DPP4
por: Lagunas-Rangel, Francisco Alejandro, et al.
Publicado: (2023)

The Dipeptidyl Peptidase (DPP)-4 Inhibitors for Type 2 Diabetes Mellitus in Challenging Patient Groups
por: Kountz, David
Publicado: (2013)

Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression
por: Kang, Eugene Yu-Chuan, et al.
Publicado: (2021)

Rebound increase in circulating dipeptidyl peptidase 4 (DPP4) enzyme activity after acute COVID-19
por: Firneisz, Gábor
Publicado: (2023)

A Case of Euglycemic Diabetic Ketoacidosis (DKA), Influenza, and a Dipeptidyl Peptidase-4 (DPP-4) Inhibitor
por: Jeong, Su Hyun, et al.
Publicado: (2023)

Glucagon-like peptide-1 (GLP-1) mediates the protective effects of dipeptidyl peptidase IV inhibition on pulmonary hypertension
por: Wang, Jingjing, et al.
Publicado: (2019)

The effect of Dipeptidyl peptidase 4 (DPP-4) inhibitors on hemoglobin level in diabetic kidney disease: A retrospective cohort study
por: Zeng, Lingfeng, et al.
Publicado: (2023)

Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
por: Mousa, Shaker A., et al.
Publicado: (2019)

Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
por: Hausenloy, Derek J, et al.
Publicado: (2013)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Downregulation of Signaling-active IGF-1 by Dipeptidyl Peptidase IV (DPP-IV)
por: Lin, Ching-Ting, et al.
Publicado: (2010)

Neuronal Roles of the Multifunctional Protein Dipeptidyl Peptidase-like 6 (DPP6)
por: Malloy, Cole, et al.
Publicado: (2022)

Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis
por: Park, Se Hee, et al.
Publicado: (2016)

Adaptive evolution of bat dipeptidyl peptidase 4 (dpp4): implications for the origin and emergence of Middle East respiratory syndrome coronavirus
por: Cui, Jie, et al.
Publicado: (2013)

The dipeptidyl peptidase‐4 (DPP‐4) inhibitor teneligliptin enhances brown adipose tissue function, thereby preventing obesity in mice
por: Takeda, Kenichiro, et al.
Publicado: (2018)

Reply to Firneisz: “Rebound increase in circulating dipeptidyl peptidase-4 (DPP4) enzyme activity after acute Covid-19”
por: Lin, Shu-Hai, et al.
Publicado: (2023)

Identification of Dipeptidyl-Peptidase (DPP)5 and DPP7 in Porphyromonas endodontalis, Distinct from Those in Porphyromonas gingivalis
por: Nishimata, Haruka, et al.
Publicado: (2014)

A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice
por: Berger, Joel P., et al.
Publicado: (2017)

Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration
por: Fujiwara, Kaori, et al.
Publicado: (2015)

Increased Plasma Dipeptidyl Peptidase-4 (DPP4) Activity Is an Obesity-Independent Parameter for Glycemic Deregulation in Type 2 Diabetes Patients
por: Sarkar, Jit, et al.
Publicado: (2019)

Clinical Features and Outcomes of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid (DPP4i-Associated BP) in Thai Patients
por: Thewjitcharoen, Yotsapon, et al.
Publicado: (2020)

The Inhibitory Effects of New Zealand Pine Bark (Enzogenol(®)) on α-Amylase, α-Glucosidase, and Dipeptidyl Peptidase-4 (DPP-4) Enzymes
por: Lim, Wen Xin Janice, et al.
Publicado: (2022)

Molecular design of near-infrared (NIR) fluorescent probes targeting exopeptidase and application for detection of dipeptidyl peptidase 4 (DPP-4) activity
por: Hoshino, Yuki, et al.
Publicado: (2022)

Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
por: Kim, Ye An, et al.
Publicado: (2015)

Acute hemodynamic and renal effects of glucagon-like peptide 1 analog and dipeptidyl peptidase-4 inhibitor in rats
por: Zhou, Xiaoyan, et al.
Publicado: (2015)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes
por: Shi, Sen, et al.
Publicado: (2016)

Inhibition of Dipeptidyl Peptidase-4 by Vildagliptin During Glucagon-Like Peptide 1 Infusion Increases Liver Glucose Uptake in the Conscious Dog
por: Edgerton, Dale S., et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_59app8j28ehuipjhrtuhl4qthg